Robert Griffin
Concepts (702)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 38 | 2024 | 1251 | 5.270 |
Why?
| Hyperthermia, Induced | 17 | 2019 | 115 | 3.630 |
Why?
| Mammary Neoplasms, Experimental | 12 | 2015 | 121 | 3.250 |
Why?
| Radiotherapy | 10 | 2021 | 125 | 2.970 |
Why?
| Air Pollutants | 13 | 2024 | 64 | 2.920 |
Why?
| Gold | 9 | 2023 | 128 | 2.580 |
Why?
| Bystander Effect | 5 | 2024 | 25 | 2.090 |
Why?
| Mice | 74 | 2024 | 5687 | 2.070 |
Why?
| Radiation-Sensitizing Agents | 11 | 2023 | 51 | 2.050 |
Why?
| Animals | 99 | 2024 | 13124 | 2.000 |
Why?
| Nanostructures | 5 | 2023 | 45 | 1.840 |
Why?
| Cell Line, Tumor | 39 | 2024 | 1398 | 1.730 |
Why?
| Exosomes | 7 | 2022 | 48 | 1.660 |
Why?
| Angiogenesis Inhibitors | 8 | 2017 | 183 | 1.570 |
Why?
| Phototherapy | 5 | 2022 | 42 | 1.560 |
Why?
| Radiation Tolerance | 9 | 2020 | 84 | 1.510 |
Why?
| Metal Nanoparticles | 4 | 2023 | 80 | 1.490 |
Why?
| Blood Vessels | 9 | 2020 | 71 | 1.470 |
Why?
| Nanoparticles | 6 | 2022 | 152 | 1.440 |
Why?
| Neoplasms, Experimental | 6 | 2020 | 110 | 1.420 |
Why?
| Galectin 1 | 4 | 2017 | 20 | 1.390 |
Why?
| Environmental Monitoring | 8 | 2024 | 66 | 1.380 |
Why?
| Aerosols | 10 | 2023 | 74 | 1.360 |
Why?
| Lung Neoplasms | 9 | 2024 | 601 | 1.350 |
Why?
| Oxygen | 12 | 2020 | 321 | 1.330 |
Why?
| Polyethylene Glycols | 4 | 2022 | 86 | 1.300 |
Why?
| Air Pollution | 3 | 2024 | 46 | 1.260 |
Why?
| Particulate Matter | 5 | 2024 | 54 | 1.240 |
Why?
| Carcinoma, Squamous Cell | 6 | 2019 | 326 | 1.220 |
Why?
| Combined Modality Therapy | 17 | 2022 | 641 | 1.110 |
Why?
| Endothelial Cells | 7 | 2021 | 258 | 1.100 |
Why?
| Humans | 107 | 2024 | 50503 | 1.080 |
Why?
| Tumor Necrosis Factor-alpha | 8 | 2019 | 393 | 1.030 |
Why?
| Sulfates | 2 | 2023 | 24 | 1.000 |
Why?
| Neovascularization, Pathologic | 9 | 2021 | 155 | 1.000 |
Why?
| Fibrosarcoma | 7 | 2019 | 12 | 1.000 |
Why?
| Apoptosis | 10 | 2024 | 1097 | 0.980 |
Why?
| Antineoplastic Agents | 13 | 2024 | 1172 | 0.930 |
Why?
| Liposomes | 2 | 2022 | 52 | 0.910 |
Why?
| Radiosurgery | 7 | 2024 | 123 | 0.900 |
Why?
| Oxygen Consumption | 4 | 2020 | 190 | 0.900 |
Why?
| Peptides | 10 | 2022 | 221 | 0.890 |
Why?
| Ozone | 6 | 2022 | 20 | 0.880 |
Why?
| Benzeneacetamides | 2 | 2024 | 12 | 0.860 |
Why?
| Glutaminase | 2 | 2024 | 18 | 0.860 |
Why?
| Fluorescent Dyes | 5 | 2022 | 103 | 0.850 |
Why?
| Mice, Inbred BALB C | 8 | 2020 | 296 | 0.850 |
Why?
| Proteins | 6 | 2010 | 339 | 0.830 |
Why?
| Pyrimidines | 10 | 2024 | 191 | 0.800 |
Why?
| Indocyanine Green | 2 | 2013 | 34 | 0.790 |
Why?
| Neoplastic Cells, Circulating | 3 | 2017 | 74 | 0.760 |
Why?
| Cell Communication | 2 | 2021 | 68 | 0.750 |
Why?
| Protein Kinase Inhibitors | 6 | 2024 | 204 | 0.750 |
Why?
| Cell Survival | 16 | 2024 | 589 | 0.720 |
Why?
| Thiadiazoles | 3 | 2024 | 18 | 0.720 |
Why?
| Flow Cytometry | 5 | 2017 | 474 | 0.710 |
Why?
| Radiotherapy, Intensity-Modulated | 4 | 2022 | 177 | 0.700 |
Why?
| Antioxidants | 2 | 2020 | 239 | 0.680 |
Why?
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 154 | 0.670 |
Why?
| Radiation-Protective Agents | 1 | 2020 | 72 | 0.660 |
Why?
| Immunotherapy | 2 | 2021 | 235 | 0.660 |
Why?
| Radiation Dosage | 2 | 2020 | 162 | 0.660 |
Why?
| Radiotherapy Dosage | 6 | 2022 | 248 | 0.640 |
Why?
| Radiotherapy Planning, Computer-Assisted | 6 | 2023 | 253 | 0.640 |
Why?
| Models, Theoretical | 7 | 2015 | 170 | 0.640 |
Why?
| Head and Neck Neoplasms | 3 | 2019 | 287 | 0.630 |
Why?
| Epigenesis, Genetic | 2 | 2019 | 372 | 0.610 |
Why?
| Aniline Compounds | 5 | 2024 | 43 | 0.610 |
Why?
| Drug Delivery Systems | 2 | 2022 | 143 | 0.600 |
Why?
| Information Dissemination | 2 | 2016 | 80 | 0.600 |
Why?
| Arsenicals | 3 | 2007 | 14 | 0.590 |
Why?
| Oxides | 3 | 2007 | 18 | 0.590 |
Why?
| Cell Proliferation | 12 | 2024 | 985 | 0.590 |
Why?
| Molecular Imaging | 2 | 2015 | 54 | 0.580 |
Why?
| Uncertainty | 2 | 2022 | 44 | 0.580 |
Why?
| Disease Models, Animal | 11 | 2020 | 1436 | 0.570 |
Why?
| Xenograft Model Antitumor Assays | 13 | 2021 | 212 | 0.570 |
Why?
| Bone and Bones | 2 | 2012 | 478 | 0.560 |
Why?
| Gamma Rays | 2 | 2020 | 47 | 0.560 |
Why?
| Oxidation-Reduction | 5 | 2023 | 316 | 0.560 |
Why?
| Female | 35 | 2021 | 27081 | 0.560 |
Why?
| Radiotherapy, Conformal | 2 | 2019 | 53 | 0.550 |
Why?
| Pneumonia, Viral | 1 | 2020 | 169 | 0.550 |
Why?
| Coronavirus Infections | 1 | 2020 | 178 | 0.540 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 123 | 0.540 |
Why?
| Science | 1 | 2016 | 17 | 0.540 |
Why?
| Wind | 3 | 2025 | 7 | 0.540 |
Why?
| Mice, Nude | 12 | 2019 | 248 | 0.540 |
Why?
| Radiobiology | 5 | 2023 | 21 | 0.530 |
Why?
| Enzyme Inhibitors | 7 | 2024 | 377 | 0.510 |
Why?
| Mouth Neoplasms | 4 | 2015 | 20 | 0.510 |
Why?
| Texas | 7 | 2024 | 142 | 0.500 |
Why?
| Pandemics | 1 | 2020 | 563 | 0.490 |
Why?
| Cell Hypoxia | 6 | 2015 | 82 | 0.480 |
Why?
| Carcinoma | 2 | 2013 | 137 | 0.460 |
Why?
| Exons | 3 | 2024 | 93 | 0.460 |
Why?
| Laser Therapy | 2 | 2013 | 83 | 0.460 |
Why?
| Solanum tuberosum | 1 | 2014 | 5 | 0.460 |
Why?
| Sanitation | 1 | 2014 | 16 | 0.450 |
Why?
| Radiation Oncology | 3 | 2024 | 23 | 0.450 |
Why?
| Conservation of Natural Resources | 4 | 2025 | 32 | 0.450 |
Why?
| Bone Marrow Neoplasms | 1 | 2013 | 13 | 0.440 |
Why?
| Coloring Agents | 2 | 2013 | 66 | 0.440 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 833 | 0.440 |
Why?
| Chemokines | 1 | 2013 | 75 | 0.430 |
Why?
| Plasmodium falciparum | 2 | 2024 | 19 | 0.430 |
Why?
| Spectrum Analysis, Raman | 3 | 2019 | 55 | 0.430 |
Why?
| Malaria, Falciparum | 2 | 2024 | 14 | 0.430 |
Why?
| Tumor Microenvironment | 7 | 2022 | 222 | 0.420 |
Why?
| Infrared Rays | 2 | 2019 | 25 | 0.420 |
Why?
| Tumor Cells, Cultured | 8 | 2019 | 457 | 0.420 |
Why?
| Signal Transduction | 8 | 2021 | 1624 | 0.410 |
Why?
| Indoles | 4 | 2024 | 278 | 0.410 |
Why?
| Cell Death | 7 | 2019 | 175 | 0.400 |
Why?
| Adult Stem Cells | 1 | 2012 | 10 | 0.400 |
Why?
| Antibodies, Monoclonal | 3 | 2020 | 462 | 0.390 |
Why?
| DNA Damage | 5 | 2019 | 301 | 0.380 |
Why?
| Lignin | 1 | 2011 | 2 | 0.380 |
Why?
| Environmental Pollution | 1 | 2011 | 10 | 0.380 |
Why?
| Bone Neoplasms | 2 | 2011 | 179 | 0.380 |
Why?
| Time Factors | 12 | 2017 | 2935 | 0.380 |
Why?
| Ecosystem | 3 | 2017 | 65 | 0.380 |
Why?
| Mice, Inbred C3H | 9 | 2015 | 85 | 0.370 |
Why?
| Models, Biological | 6 | 2018 | 716 | 0.370 |
Why?
| Dose-Response Relationship, Radiation | 10 | 2020 | 183 | 0.370 |
Why?
| Photochemical Processes | 1 | 2010 | 9 | 0.360 |
Why?
| Saliva | 3 | 2007 | 55 | 0.360 |
Why?
| Photons | 2 | 2020 | 19 | 0.360 |
Why?
| Phenols | 1 | 2011 | 82 | 0.360 |
Why?
| Cytokines | 1 | 2013 | 606 | 0.350 |
Why?
| Cell Line | 6 | 2021 | 988 | 0.340 |
Why?
| Melanoma, Experimental | 2 | 2021 | 40 | 0.340 |
Why?
| Breast Neoplasms | 6 | 2017 | 1201 | 0.340 |
Why?
| Methionine | 3 | 2020 | 134 | 0.340 |
Why?
| Rats | 11 | 2022 | 3292 | 0.340 |
Why?
| Mutagenesis, Insertional | 3 | 2024 | 22 | 0.330 |
Why?
| Radiation Injuries | 3 | 2020 | 112 | 0.330 |
Why?
| Volatile Organic Compounds | 2 | 2022 | 5 | 0.320 |
Why?
| Hydroxyl Radical | 2 | 2010 | 7 | 0.320 |
Why?
| Glutamine | 3 | 2024 | 175 | 0.320 |
Why?
| Atmosphere | 4 | 2019 | 9 | 0.310 |
Why?
| Receptor, erbB-2 | 5 | 2016 | 75 | 0.310 |
Why?
| Reactive Oxygen Species | 3 | 2024 | 409 | 0.310 |
Why?
| Radiation | 2 | 2020 | 15 | 0.310 |
Why?
| Weightlessness Simulation | 2 | 2020 | 22 | 0.300 |
Why?
| Drug Carriers | 2 | 2013 | 70 | 0.300 |
Why?
| Precancerous Conditions | 2 | 2010 | 82 | 0.300 |
Why?
| History, 20th Century | 3 | 2020 | 100 | 0.300 |
Why?
| Caspase Inhibitors | 1 | 2008 | 16 | 0.300 |
Why?
| Cell Membrane Permeability | 1 | 2008 | 28 | 0.290 |
Why?
| Cities | 3 | 2024 | 19 | 0.290 |
Why?
| Mice, SCID | 3 | 2024 | 178 | 0.290 |
Why?
| China | 3 | 2023 | 90 | 0.290 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 28 | 0.290 |
Why?
| Forecasting | 4 | 2020 | 147 | 0.290 |
Why?
| Carbon Radioisotopes | 2 | 2024 | 53 | 0.290 |
Why?
| Nanomedicine | 2 | 2024 | 20 | 0.290 |
Why?
| Freezing | 2 | 2004 | 16 | 0.280 |
Why?
| Male | 20 | 2024 | 25907 | 0.280 |
Why?
| Caspases | 1 | 2007 | 103 | 0.280 |
Why?
| Adenocarcinoma | 1 | 2011 | 397 | 0.280 |
Why?
| Vascular Neoplasms | 1 | 2007 | 17 | 0.270 |
Why?
| Nanotubes, Carbon | 2 | 2017 | 68 | 0.270 |
Why?
| Radiotherapy, Image-Guided | 2 | 2016 | 23 | 0.270 |
Why?
| Risk Assessment | 3 | 2017 | 1270 | 0.260 |
Why?
| Glutathione | 2 | 2019 | 299 | 0.260 |
Why?
| Melanoma | 2 | 2020 | 280 | 0.260 |
Why?
| Microscopy, Fluorescence | 3 | 2018 | 158 | 0.260 |
Why?
| Cryotherapy | 2 | 2011 | 12 | 0.250 |
Why?
| Organs at Risk | 3 | 2022 | 71 | 0.250 |
Why?
| Energy-Generating Resources | 1 | 2025 | 1 | 0.240 |
Why?
| Renewable Energy | 1 | 2025 | 1 | 0.240 |
Why?
| Hindlimb | 2 | 2004 | 30 | 0.240 |
Why?
| Fisheries | 1 | 2025 | 8 | 0.240 |
Why?
| Tyrosine-tRNA Ligase | 1 | 2024 | 1 | 0.240 |
Why?
| Administration, Oral | 6 | 2024 | 434 | 0.240 |
Why?
| Ovarian Neoplasms | 2 | 2008 | 450 | 0.240 |
Why?
| Hydrogen-Ion Concentration | 5 | 2005 | 168 | 0.240 |
Why?
| Antimalarials | 1 | 2024 | 24 | 0.230 |
Why?
| Doxorubicin | 2 | 2024 | 236 | 0.230 |
Why?
| Cell Culture Techniques | 2 | 2019 | 96 | 0.230 |
Why?
| Disease Progression | 4 | 2019 | 829 | 0.230 |
Why?
| Endocytosis | 1 | 2024 | 55 | 0.230 |
Why?
| Oxidants, Photochemical | 1 | 2004 | 3 | 0.230 |
Why?
| Smog | 1 | 2004 | 5 | 0.230 |
Why?
| Porphyrins | 1 | 2023 | 10 | 0.220 |
Why?
| Oxidants | 1 | 2004 | 54 | 0.220 |
Why?
| Nitroimidazoles | 2 | 2015 | 16 | 0.220 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2017 | 182 | 0.220 |
Why?
| Clinical Trials as Topic | 3 | 2023 | 486 | 0.220 |
Why?
| Proteomics | 4 | 2021 | 314 | 0.220 |
Why?
| Radiometry | 2 | 2016 | 123 | 0.220 |
Why?
| Photochemotherapy | 1 | 2023 | 33 | 0.220 |
Why?
| Sulfur Oxides | 1 | 2023 | 1 | 0.210 |
Why?
| Gulf of Mexico | 1 | 2023 | 5 | 0.210 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2021 | 116 | 0.210 |
Why?
| Receptor Protein-Tyrosine Kinases | 2 | 2008 | 46 | 0.210 |
Why?
| Carcinoma, Hepatocellular | 2 | 2023 | 195 | 0.210 |
Why?
| Partial Pressure | 3 | 2011 | 14 | 0.210 |
Why?
| Environmental Exposure | 2 | 2022 | 200 | 0.210 |
Why?
| Halogens | 1 | 2022 | 3 | 0.210 |
Why?
| Phosphatidylethanolamines | 1 | 2022 | 10 | 0.210 |
Why?
| Organic Anion Transporters | 1 | 2022 | 1 | 0.210 |
Why?
| Oceans and Seas | 2 | 2025 | 25 | 0.210 |
Why?
| Tumor Burden | 3 | 2010 | 130 | 0.210 |
Why?
| Lipid Bilayers | 1 | 2022 | 12 | 0.210 |
Why?
| Bile | 1 | 2022 | 23 | 0.210 |
Why?
| Chloral Hydrate | 1 | 2022 | 18 | 0.200 |
Why?
| Parasites | 1 | 2002 | 3 | 0.200 |
Why?
| Water Pollution | 1 | 2002 | 8 | 0.200 |
Why?
| Tissue Distribution | 1 | 2022 | 166 | 0.200 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.200 |
Why?
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 4 | 0.200 |
Why?
| Receptors, Growth Factor | 1 | 2002 | 7 | 0.200 |
Why?
| X-Rays | 3 | 2016 | 55 | 0.200 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 3 | 2007 | 13 | 0.200 |
Why?
| Biological Transport | 2 | 2021 | 164 | 0.200 |
Why?
| Naphthoquinones | 3 | 2007 | 10 | 0.200 |
Why?
| Protons | 1 | 2022 | 67 | 0.200 |
Why?
| Liver Neoplasms | 2 | 2023 | 326 | 0.190 |
Why?
| Cholesterol | 1 | 2022 | 150 | 0.190 |
Why?
| Pyrroles | 1 | 2002 | 68 | 0.190 |
Why?
| Boron Compounds | 1 | 2021 | 19 | 0.190 |
Why?
| Floods | 1 | 2021 | 2 | 0.190 |
Why?
| Neoplasm Proteins | 3 | 2017 | 320 | 0.190 |
Why?
| Nucleotides, Cyclic | 1 | 2021 | 4 | 0.190 |
Why?
| Spheroids, Cellular | 3 | 2019 | 24 | 0.190 |
Why?
| High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.190 |
Why?
| Optical Imaging | 2 | 2020 | 23 | 0.190 |
Why?
| Endosomes | 1 | 2021 | 32 | 0.180 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2021 | 18 | 0.180 |
Why?
| Radiation, Ionizing | 4 | 2018 | 100 | 0.180 |
Why?
| Cells, Cultured | 4 | 2020 | 1571 | 0.180 |
Why?
| Proteasome Inhibitors | 1 | 2021 | 104 | 0.180 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 57 | 0.180 |
Why?
| Proton Therapy | 1 | 2020 | 11 | 0.180 |
Why?
| Protein Binding | 4 | 2020 | 654 | 0.180 |
Why?
| Cell Transformation, Neoplastic | 3 | 2018 | 181 | 0.180 |
Why?
| Spectrum Analysis | 1 | 2020 | 70 | 0.170 |
Why?
| Thymus Gland | 1 | 2020 | 42 | 0.170 |
Why?
| Chronic Pain | 1 | 2023 | 182 | 0.170 |
Why?
| History, 21st Century | 1 | 2020 | 56 | 0.170 |
Why?
| Neural Stem Cells | 1 | 2020 | 26 | 0.170 |
Why?
| Cell Differentiation | 2 | 2020 | 640 | 0.170 |
Why?
| Adenosine Triphosphate | 1 | 2021 | 232 | 0.170 |
Why?
| Public Health | 1 | 2002 | 199 | 0.170 |
Why?
| Heavy Ion Radiotherapy | 1 | 2019 | 2 | 0.170 |
Why?
| Receptor, TIE-2 | 2 | 2017 | 16 | 0.170 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 9 | 0.170 |
Why?
| Spleen | 1 | 2020 | 169 | 0.170 |
Why?
| Calixarenes | 2 | 2017 | 9 | 0.170 |
Why?
| Autoantibodies | 1 | 2020 | 117 | 0.170 |
Why?
| Societies, Medical | 1 | 2020 | 187 | 0.160 |
Why?
| Interleukin-6 | 2 | 2020 | 261 | 0.160 |
Why?
| Whole-Body Irradiation | 1 | 2020 | 132 | 0.160 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 135 | 0.160 |
Why?
| Cone-Beam Computed Tomography | 2 | 2016 | 33 | 0.160 |
Why?
| Preservation, Biological | 1 | 2018 | 8 | 0.160 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 76 | 0.160 |
Why?
| Drug Evaluation, Preclinical | 3 | 2015 | 145 | 0.160 |
Why?
| Membrane Proteins | 1 | 2021 | 332 | 0.160 |
Why?
| Ephrin-B2 | 1 | 2018 | 5 | 0.160 |
Why?
| Cystic Fibrosis | 1 | 2021 | 147 | 0.160 |
Why?
| Astrocytes | 1 | 2020 | 145 | 0.150 |
Why?
| Paracrine Communication | 1 | 2018 | 12 | 0.150 |
Why?
| Methionine Adenosyltransferase | 1 | 2018 | 19 | 0.150 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 125 | 0.150 |
Why?
| Myocytes, Cardiac | 1 | 2019 | 123 | 0.150 |
Why?
| Treatment Outcome | 5 | 2020 | 5283 | 0.150 |
Why?
| Environmental Pollutants | 1 | 2020 | 102 | 0.150 |
Why?
| Lipopolysaccharides | 1 | 2019 | 197 | 0.150 |
Why?
| Microinjections | 1 | 2018 | 29 | 0.150 |
Why?
| Biological Assay | 1 | 2018 | 45 | 0.150 |
Why?
| Calibration | 1 | 2018 | 57 | 0.150 |
Why?
| Prostatic Neoplasms | 2 | 2013 | 384 | 0.150 |
Why?
| Galectins | 1 | 2018 | 5 | 0.150 |
Why?
| Ubiquitin-Activating Enzymes | 1 | 2018 | 4 | 0.150 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 102 | 0.150 |
Why?
| Nucleosides | 1 | 2018 | 5 | 0.150 |
Why?
| Indazoles | 1 | 2018 | 46 | 0.150 |
Why?
| Gastrointestinal Tract | 1 | 2019 | 103 | 0.150 |
Why?
| Erythrocyte Membrane | 1 | 2017 | 14 | 0.150 |
Why?
| California | 4 | 2010 | 86 | 0.150 |
Why?
| MicroRNAs | 1 | 2021 | 344 | 0.140 |
Why?
| Particle Size | 2 | 2024 | 80 | 0.140 |
Why?
| Scavenger Receptors, Class E | 1 | 2019 | 203 | 0.140 |
Why?
| Histocompatibility Antigens Class II | 1 | 2017 | 37 | 0.140 |
Why?
| Models, Molecular | 4 | 2021 | 334 | 0.140 |
Why?
| Small Molecule Libraries | 1 | 2018 | 67 | 0.140 |
Why?
| United States | 5 | 2025 | 4955 | 0.140 |
Why?
| Epitope Mapping | 1 | 2017 | 6 | 0.140 |
Why?
| Vehicle Emissions | 1 | 2017 | 9 | 0.140 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 22 | 0.140 |
Why?
| Bacteria | 1 | 2018 | 218 | 0.140 |
Why?
| Silver | 1 | 2017 | 48 | 0.140 |
Why?
| Myocardial Infarction | 1 | 2021 | 403 | 0.140 |
Why?
| Pyridazines | 2 | 2008 | 11 | 0.140 |
Why?
| Ammonia | 1 | 2017 | 78 | 0.140 |
Why?
| Sulfonamides | 1 | 2018 | 126 | 0.140 |
Why?
| Random Allocation | 2 | 2015 | 289 | 0.130 |
Why?
| Epithelial Cells | 1 | 2018 | 207 | 0.130 |
Why?
| Biomass | 1 | 2016 | 18 | 0.130 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1000 | 0.130 |
Why?
| Mice, Inbred Strains | 3 | 2013 | 160 | 0.130 |
Why?
| Dendritic Cells | 1 | 2017 | 135 | 0.130 |
Why?
| Antibodies | 1 | 2017 | 153 | 0.130 |
Why?
| Radiation Protection | 1 | 2016 | 47 | 0.130 |
Why?
| Extraterrestrial Environment | 1 | 2016 | 7 | 0.130 |
Why?
| Neoplasm Transplantation | 2 | 2007 | 86 | 0.130 |
Why?
| Chemistry, Organic | 2 | 2019 | 2 | 0.130 |
Why?
| Cyclonic Storms | 1 | 2015 | 6 | 0.130 |
Why?
| Organ Specificity | 1 | 2016 | 109 | 0.130 |
Why?
| Extracellular Fluid | 1 | 2015 | 14 | 0.130 |
Why?
| Tomography, Spiral Computed | 1 | 2016 | 56 | 0.120 |
Why?
| Microbubbles | 1 | 2015 | 25 | 0.120 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2016 | 91 | 0.120 |
Why?
| Multiple Myeloma | 1 | 2010 | 2998 | 0.120 |
Why?
| Organ Sparing Treatments | 1 | 2016 | 56 | 0.120 |
Why?
| Sulfuric Acids | 1 | 2015 | 8 | 0.120 |
Why?
| Cell Count | 1 | 2015 | 150 | 0.120 |
Why?
| Stromal Cells | 1 | 2015 | 75 | 0.120 |
Why?
| Pressure | 1 | 2015 | 104 | 0.120 |
Why?
| Structure-Activity Relationship | 6 | 2021 | 395 | 0.120 |
Why?
| Rabbits | 3 | 2010 | 372 | 0.120 |
Why?
| Necrosis | 3 | 2013 | 174 | 0.120 |
Why?
| Biomedical Research | 1 | 2018 | 244 | 0.120 |
Why?
| Tandem Mass Spectrometry | 3 | 2017 | 238 | 0.120 |
Why?
| Imaging, Three-Dimensional | 1 | 2015 | 150 | 0.120 |
Why?
| Carbon Dioxide | 2 | 2005 | 95 | 0.110 |
Why?
| Cisplatin | 2 | 2024 | 286 | 0.110 |
Why?
| Image Processing, Computer-Assisted | 1 | 2016 | 243 | 0.110 |
Why?
| Hot Temperature | 3 | 2013 | 198 | 0.110 |
Why?
| Brain | 2 | 2020 | 1319 | 0.110 |
Why?
| Mexico | 1 | 2014 | 35 | 0.110 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2017 | 475 | 0.110 |
Why?
| Contrast Media | 1 | 2015 | 192 | 0.110 |
Why?
| Animals, Inbred Strains | 1 | 2013 | 5 | 0.110 |
Why?
| DNA Methylation | 1 | 2018 | 550 | 0.110 |
Why?
| Ultrasonography | 1 | 2015 | 435 | 0.110 |
Why?
| Nanoconjugates | 1 | 2013 | 1 | 0.110 |
Why?
| Ions | 2 | 2024 | 31 | 0.110 |
Why?
| Stress, Psychological | 1 | 2015 | 266 | 0.110 |
Why?
| Food, Genetically Modified | 1 | 2013 | 1 | 0.110 |
Why?
| Food Labeling | 1 | 2013 | 6 | 0.110 |
Why?
| Societies, Scientific | 1 | 2013 | 14 | 0.110 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 181 | 0.100 |
Why?
| Nanospheres | 1 | 2013 | 8 | 0.100 |
Why?
| Nanotechnology | 1 | 2013 | 36 | 0.100 |
Why?
| Nutrition Policy | 1 | 2013 | 39 | 0.100 |
Why?
| Gene Expression Profiling | 2 | 2017 | 1025 | 0.100 |
Why?
| Mice, Inbred C57BL | 4 | 2020 | 1808 | 0.100 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 572 | 0.100 |
Why?
| Linear Models | 1 | 2013 | 279 | 0.100 |
Why?
| Blotting, Western | 1 | 2013 | 578 | 0.100 |
Why?
| Film Dosimetry | 1 | 2012 | 15 | 0.100 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 405 | 0.100 |
Why?
| Glucose | 2 | 2011 | 341 | 0.100 |
Why?
| RNA, Messenger | 2 | 2013 | 1089 | 0.100 |
Why?
| North Carolina | 2 | 2022 | 52 | 0.100 |
Why?
| Gold Colloid | 2 | 2011 | 2 | 0.100 |
Why?
| Acids | 1 | 2011 | 11 | 0.100 |
Why?
| Isomerism | 1 | 2011 | 24 | 0.100 |
Why?
| Gene Expression Regulation | 3 | 2021 | 955 | 0.100 |
Why?
| Copper | 1 | 2011 | 42 | 0.090 |
Why?
| Feces | 2 | 2024 | 134 | 0.090 |
Why?
| Injections, Intravenous | 1 | 2011 | 137 | 0.090 |
Why?
| Aldehydes | 1 | 2011 | 82 | 0.090 |
Why?
| Immunohistochemistry | 2 | 2020 | 957 | 0.090 |
Why?
| Acenaphthenes | 1 | 2010 | 1 | 0.090 |
Why?
| Nitrogen Oxides | 1 | 2010 | 3 | 0.090 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2024 | 131 | 0.090 |
Why?
| Positron-Emission Tomography | 1 | 2012 | 292 | 0.090 |
Why?
| Myosins | 1 | 2010 | 17 | 0.090 |
Why?
| Middle Aged | 5 | 2024 | 12611 | 0.090 |
Why?
| Bone Transplantation | 1 | 2010 | 45 | 0.090 |
Why?
| Isoxazoles | 1 | 2009 | 14 | 0.080 |
Why?
| Nitrous Acid | 1 | 2009 | 1 | 0.080 |
Why?
| Free Radicals | 1 | 2009 | 27 | 0.080 |
Why?
| Actins | 1 | 2010 | 114 | 0.080 |
Why?
| Abdomen | 1 | 2010 | 75 | 0.080 |
Why?
| Acetylcysteine | 1 | 2010 | 101 | 0.080 |
Why?
| Microcirculation | 1 | 2010 | 72 | 0.080 |
Why?
| Adult | 5 | 2024 | 13577 | 0.080 |
Why?
| Protein Transport | 1 | 2010 | 181 | 0.080 |
Why?
| Naphthalenes | 1 | 2010 | 121 | 0.080 |
Why?
| Formaldehyde | 1 | 2009 | 49 | 0.080 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2009 | 49 | 0.080 |
Why?
| Glycolysis | 2 | 2021 | 69 | 0.080 |
Why?
| Coculture Techniques | 2 | 2020 | 142 | 0.080 |
Why?
| Chemotherapy, Adjuvant | 2 | 2016 | 121 | 0.080 |
Why?
| Prospective Studies | 3 | 2023 | 2378 | 0.080 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2009 | 35 | 0.080 |
Why?
| Glycogen Synthase Kinase 3 | 2 | 2008 | 20 | 0.080 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2008 | 11 | 0.080 |
Why?
| Growth Inhibitors | 2 | 2009 | 27 | 0.080 |
Why?
| STAT3 Transcription Factor | 2 | 2020 | 77 | 0.080 |
Why?
| Up-Regulation | 2 | 2007 | 446 | 0.080 |
Why?
| Methotrexate | 1 | 2009 | 72 | 0.080 |
Why?
| Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 27 | 0.080 |
Why?
| Nerve Tissue Proteins | 2 | 2020 | 194 | 0.080 |
Why?
| Drinking | 2 | 2020 | 38 | 0.080 |
Why?
| Insulin-Like Growth Factor I | 1 | 2009 | 136 | 0.080 |
Why?
| Alkynes | 1 | 2008 | 5 | 0.080 |
Why?
| Pyrrolidines | 1 | 2008 | 67 | 0.070 |
Why?
| HEK293 Cells | 2 | 2020 | 213 | 0.070 |
Why?
| Cytotoxins | 1 | 2008 | 15 | 0.070 |
Why?
| Regional Blood Flow | 2 | 2005 | 109 | 0.070 |
Why?
| Cryosurgery | 2 | 2011 | 36 | 0.070 |
Why?
| Chemical Fractionation | 1 | 2007 | 16 | 0.070 |
Why?
| Drug Synergism | 2 | 2005 | 151 | 0.070 |
Why?
| Skin | 2 | 2009 | 388 | 0.070 |
Why?
| Fluorescence | 2 | 2018 | 41 | 0.070 |
Why?
| Toxicity Tests | 1 | 2008 | 54 | 0.070 |
Why?
| Oxidative Stress | 1 | 2012 | 772 | 0.070 |
Why?
| Surface Plasmon Resonance | 2 | 2017 | 21 | 0.070 |
Why?
| Cost-Benefit Analysis | 2 | 2021 | 266 | 0.070 |
Why?
| Computer Simulation | 3 | 2016 | 279 | 0.070 |
Why?
| Enzyme Activation | 2 | 2005 | 268 | 0.070 |
Why?
| In Situ Nick-End Labeling | 2 | 2004 | 52 | 0.070 |
Why?
| Histones | 2 | 2020 | 297 | 0.070 |
Why?
| Sesquiterpenes | 1 | 2008 | 88 | 0.070 |
Why?
| Hearing Loss, Sensorineural | 1 | 2008 | 76 | 0.070 |
Why?
| Sulfides | 2 | 2018 | 28 | 0.070 |
Why?
| Neurons | 2 | 2020 | 452 | 0.070 |
Why?
| Angiopoietin-2 | 2 | 2017 | 15 | 0.070 |
Why?
| Angiopoietin-1 | 2 | 2017 | 16 | 0.070 |
Why?
| Concept Formation | 1 | 2006 | 12 | 0.070 |
Why?
| Fibroblast Growth Factor 2 | 2 | 2017 | 34 | 0.070 |
Why?
| Interleukin-2 | 1 | 2006 | 71 | 0.070 |
Why?
| Interleukin-8 | 1 | 2006 | 85 | 0.070 |
Why?
| Lasers | 2 | 2019 | 106 | 0.070 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2017 | 88 | 0.070 |
Why?
| Temperature | 3 | 2018 | 162 | 0.060 |
Why?
| Sarcoma | 1 | 2007 | 65 | 0.060 |
Why?
| Mice, Inbred A | 2 | 2003 | 15 | 0.060 |
Why?
| Electrophoresis | 1 | 2005 | 16 | 0.060 |
Why?
| Feasibility Studies | 2 | 2022 | 390 | 0.060 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 859 | 0.060 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 226 | 0.060 |
Why?
| Neoadjuvant Therapy | 2 | 2017 | 120 | 0.060 |
Why?
| Carbon | 1 | 2005 | 55 | 0.060 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 60 | 0.060 |
Why?
| Colorectal Neoplasms | 2 | 2006 | 260 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2006 | 128 | 0.060 |
Why?
| Electricity | 1 | 2025 | 7 | 0.060 |
Why?
| Alkanes | 1 | 2005 | 8 | 0.060 |
Why?
| Neoplasm Staging | 2 | 2019 | 746 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 138 | 0.060 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 71 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2006 | 161 | 0.060 |
Why?
| Niacinamide | 1 | 2005 | 23 | 0.060 |
Why?
| Transplantation, Heterologous | 2 | 2021 | 75 | 0.060 |
Why?
| Protozoan Proteins | 1 | 2024 | 32 | 0.060 |
Why?
| Organelles | 1 | 2024 | 15 | 0.060 |
Why?
| Young Adult | 2 | 2024 | 4102 | 0.060 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 629 | 0.060 |
Why?
| Congresses as Topic | 1 | 2024 | 48 | 0.060 |
Why?
| Rats, Inbred F344 | 1 | 2005 | 197 | 0.060 |
Why?
| Kidney Diseases | 1 | 2007 | 213 | 0.060 |
Why?
| Administration, Inhalation | 1 | 2005 | 112 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 4 | 2009 | 1372 | 0.060 |
Why?
| MCF-7 Cells | 1 | 2024 | 62 | 0.060 |
Why?
| Amines | 1 | 2004 | 41 | 0.060 |
Why?
| Lichen Planus, Oral | 1 | 2004 | 1 | 0.060 |
Why?
| Materials Testing | 1 | 2024 | 56 | 0.060 |
Why?
| Leukoplakia, Oral | 1 | 2004 | 6 | 0.060 |
Why?
| Drug Combinations | 2 | 2018 | 127 | 0.060 |
Why?
| Photochemistry | 1 | 2004 | 15 | 0.060 |
Why?
| Hydrocarbons | 1 | 2004 | 5 | 0.060 |
Why?
| Binding Sites | 2 | 2021 | 362 | 0.060 |
Why?
| Buthionine Sulfoximine | 1 | 2024 | 13 | 0.060 |
Why?
| Photoacoustic Techniques | 2 | 2016 | 71 | 0.060 |
Why?
| Biological Availability | 1 | 2024 | 102 | 0.060 |
Why?
| Cations | 1 | 2023 | 10 | 0.060 |
Why?
| Monoterpenes | 1 | 2003 | 2 | 0.060 |
Why?
| Carboplatin | 1 | 2024 | 54 | 0.060 |
Why?
| Biocompatible Materials | 1 | 2024 | 66 | 0.060 |
Why?
| Phosphorylation | 3 | 2017 | 525 | 0.060 |
Why?
| Antibiotics, Antineoplastic | 1 | 2024 | 77 | 0.060 |
Why?
| Photosensitizing Agents | 1 | 2023 | 19 | 0.060 |
Why?
| Statistics, Nonparametric | 1 | 2004 | 192 | 0.060 |
Why?
| Multicenter Studies as Topic | 1 | 2023 | 89 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2019 | 285 | 0.050 |
Why?
| Organic Chemicals | 1 | 2003 | 14 | 0.050 |
Why?
| Sphingomyelin Phosphodiesterase | 1 | 2003 | 11 | 0.050 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 31 | 0.050 |
Why?
| Hepatitis B virus | 1 | 2023 | 26 | 0.050 |
Why?
| DNA-Binding Proteins | 1 | 2006 | 418 | 0.050 |
Why?
| Prognosis | 2 | 2009 | 1978 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2005 | 251 | 0.050 |
Why?
| Aged | 3 | 2021 | 9741 | 0.050 |
Why?
| G2 Phase | 1 | 2003 | 13 | 0.050 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 30 | 0.050 |
Why?
| Quinazolines | 1 | 2003 | 32 | 0.050 |
Why?
| Mammary Neoplasms, Animal | 1 | 2003 | 35 | 0.050 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2004 | 213 | 0.050 |
Why?
| Anions | 1 | 2022 | 7 | 0.050 |
Why?
| Consensus | 1 | 2023 | 160 | 0.050 |
Why?
| Analysis of Variance | 1 | 2004 | 552 | 0.050 |
Why?
| Interferons | 1 | 2022 | 38 | 0.050 |
Why?
| Acetone | 1 | 2022 | 7 | 0.050 |
Why?
| Rifampin | 1 | 2022 | 59 | 0.050 |
Why?
| Hepatocytes | 1 | 2023 | 178 | 0.050 |
Why?
| Polyphosphates | 1 | 2022 | 2 | 0.050 |
Why?
| Inositol | 1 | 2022 | 19 | 0.050 |
Why?
| Heating | 1 | 2022 | 6 | 0.050 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 22 | 0.050 |
Why?
| Propionates | 1 | 2002 | 22 | 0.050 |
Why?
| Pain Measurement | 1 | 2023 | 270 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2022 | 1197 | 0.050 |
Why?
| Demography | 1 | 2022 | 94 | 0.050 |
Why?
| Ferrets | 1 | 2021 | 6 | 0.050 |
Why?
| Protein Isoforms | 1 | 2022 | 116 | 0.050 |
Why?
| Pain Management | 1 | 2023 | 180 | 0.050 |
Why?
| Estuaries | 1 | 2021 | 1 | 0.050 |
Why?
| Drug Resistance, Neoplasm | 1 | 2024 | 316 | 0.050 |
Why?
| Bays | 1 | 2021 | 2 | 0.050 |
Why?
| Hydrodynamics | 1 | 2021 | 8 | 0.050 |
Why?
| San Francisco | 1 | 2021 | 12 | 0.050 |
Why?
| Models, Economic | 1 | 2021 | 17 | 0.050 |
Why?
| Income | 1 | 2022 | 104 | 0.050 |
Why?
| Catalytic Domain | 1 | 2021 | 58 | 0.050 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 91 | 0.050 |
Why?
| Protein Structure, Tertiary | 2 | 2017 | 245 | 0.050 |
Why?
| Cricetinae | 1 | 2021 | 188 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 291 | 0.050 |
Why?
| Half-Life | 1 | 2021 | 86 | 0.050 |
Why?
| Phosphates | 1 | 2021 | 46 | 0.050 |
Why?
| Analgesics, Opioid | 1 | 2007 | 575 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2021 | 70 | 0.050 |
Why?
| Molecular Docking Simulation | 1 | 2021 | 73 | 0.050 |
Why?
| Bayes Theorem | 1 | 2021 | 107 | 0.050 |
Why?
| Micronucleus Tests | 1 | 2020 | 6 | 0.050 |
Why?
| ROC Curve | 1 | 2021 | 226 | 0.050 |
Why?
| Cell Line, Transformed | 1 | 2021 | 73 | 0.050 |
Why?
| Software | 2 | 2016 | 276 | 0.050 |
Why?
| Catecholamines | 1 | 2020 | 47 | 0.040 |
Why?
| Limbic Encephalitis | 1 | 2020 | 2 | 0.040 |
Why?
| Elastin | 1 | 2020 | 22 | 0.040 |
Why?
| Monte Carlo Method | 1 | 2020 | 85 | 0.040 |
Why?
| Primary Cell Culture | 1 | 2020 | 60 | 0.040 |
Why?
| ADAM Proteins | 1 | 2020 | 20 | 0.040 |
Why?
| Epitopes | 1 | 2020 | 59 | 0.040 |
Why?
| Autoantigens | 1 | 2020 | 48 | 0.040 |
Why?
| Antiviral Agents | 1 | 2021 | 170 | 0.040 |
Why?
| HeLa Cells | 1 | 2020 | 247 | 0.040 |
Why?
| Cytoprotection | 1 | 2019 | 34 | 0.040 |
Why?
| Facility Design and Construction | 1 | 2019 | 3 | 0.040 |
Why?
| Endothelium | 1 | 2019 | 37 | 0.040 |
Why?
| Energy Intake | 1 | 2020 | 176 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 62 | 0.040 |
Why?
| Glioma | 1 | 2020 | 77 | 0.040 |
Why?
| Stress, Physiological | 1 | 2020 | 171 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 53 | 0.040 |
Why?
| Pancreatic Neoplasms | 1 | 2002 | 206 | 0.040 |
Why?
| Swine | 2 | 2011 | 408 | 0.040 |
Why?
| Skin Neoplasms | 1 | 2004 | 491 | 0.040 |
Why?
| Diffusion Chambers, Culture | 1 | 2018 | 6 | 0.040 |
Why?
| Culture Media, Serum-Free | 1 | 2018 | 15 | 0.040 |
Why?
| Specimen Handling | 1 | 2018 | 55 | 0.040 |
Why?
| Culture Media, Conditioned | 1 | 2018 | 47 | 0.040 |
Why?
| Hep G2 Cells | 1 | 2018 | 36 | 0.040 |
Why?
| Laminin | 1 | 2018 | 18 | 0.040 |
Why?
| Program Development | 1 | 2019 | 162 | 0.040 |
Why?
| Flavin-Adenine Dinucleotide | 1 | 2018 | 4 | 0.040 |
Why?
| Dextrans | 1 | 2018 | 15 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2004 | 2242 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2018 | 55 | 0.040 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 36 | 0.040 |
Why?
| NAD | 1 | 2018 | 41 | 0.040 |
Why?
| Body Weight | 1 | 2020 | 517 | 0.040 |
Why?
| Hippocampus | 1 | 2020 | 222 | 0.040 |
Why?
| Surface Properties | 1 | 2018 | 72 | 0.040 |
Why?
| Proteoglycans | 1 | 2018 | 83 | 0.040 |
Why?
| Autophagy | 1 | 2019 | 170 | 0.040 |
Why?
| Imides | 1 | 2018 | 1 | 0.040 |
Why?
| Mid-Atlantic Region | 1 | 2017 | 6 | 0.040 |
Why?
| Human Activities | 1 | 2017 | 3 | 0.040 |
Why?
| New England | 1 | 2017 | 9 | 0.040 |
Why?
| Carbohydrates | 1 | 2018 | 38 | 0.040 |
Why?
| Macaca fascicularis | 1 | 2017 | 10 | 0.040 |
Why?
| Caco-2 Cells | 1 | 2017 | 26 | 0.040 |
Why?
| Ubiquitin | 1 | 2018 | 45 | 0.040 |
Why?
| Cooperative Behavior | 1 | 2019 | 225 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2018 | 109 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2018 | 95 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2018 | 232 | 0.040 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 198 | 0.040 |
Why?
| Phagocytosis | 1 | 2017 | 44 | 0.040 |
Why?
| Cell Movement | 1 | 2018 | 247 | 0.040 |
Why?
| Nanotubes | 1 | 2017 | 27 | 0.040 |
Why?
| Inflammation | 1 | 2021 | 610 | 0.030 |
Why?
| Drug Interactions | 1 | 2017 | 206 | 0.030 |
Why?
| Collagen | 1 | 2018 | 204 | 0.030 |
Why?
| Cohort Studies | 1 | 2021 | 1452 | 0.030 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2017 | 45 | 0.030 |
Why?
| Cricetulus | 1 | 2017 | 97 | 0.030 |
Why?
| Pyrazoles | 1 | 2018 | 111 | 0.030 |
Why?
| CHO Cells | 1 | 2017 | 118 | 0.030 |
Why?
| Gene Frequency | 1 | 2017 | 97 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 384 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 231 | 0.030 |
Why?
| DNA Repair | 1 | 2018 | 188 | 0.030 |
Why?
| Fires | 1 | 2016 | 14 | 0.030 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2016 | 9 | 0.030 |
Why?
| Taxoids | 1 | 2016 | 37 | 0.030 |
Why?
| Platelet-Derived Growth Factor | 1 | 2016 | 22 | 0.030 |
Why?
| Interleukin-1alpha | 1 | 2016 | 10 | 0.030 |
Why?
| Diet | 1 | 2020 | 568 | 0.030 |
Why?
| Receptors, Progesterone | 1 | 2016 | 64 | 0.030 |
Why?
| Hindlimb Suspension | 1 | 2016 | 37 | 0.030 |
Why?
| Wetlands | 1 | 2015 | 2 | 0.030 |
Why?
| Regression Analysis | 1 | 2017 | 382 | 0.030 |
Why?
| Particle Accelerators | 1 | 2016 | 51 | 0.030 |
Why?
| Dicumarol | 2 | 2005 | 3 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2016 | 168 | 0.030 |
Why?
| Ecology | 1 | 2015 | 14 | 0.030 |
Why?
| Carbonic Anhydrases | 1 | 2015 | 3 | 0.030 |
Why?
| Molecular Structure | 2 | 2008 | 296 | 0.030 |
Why?
| Receptors, Estrogen | 1 | 2016 | 132 | 0.030 |
Why?
| Energy Metabolism | 1 | 2018 | 286 | 0.030 |
Why?
| Genotype | 1 | 2017 | 533 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2015 | 59 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2016 | 71 | 0.030 |
Why?
| Sulfur Dioxide | 1 | 2015 | 4 | 0.030 |
Why?
| Public Policy | 1 | 2015 | 35 | 0.030 |
Why?
| Models, Animal | 1 | 2016 | 227 | 0.030 |
Why?
| Norepinephrine | 1 | 2015 | 114 | 0.030 |
Why?
| Epinephrine | 1 | 2015 | 97 | 0.030 |
Why?
| Mice, Knockout | 1 | 2017 | 844 | 0.030 |
Why?
| Risk | 1 | 2015 | 324 | 0.030 |
Why?
| Weight Gain | 1 | 2016 | 237 | 0.030 |
Why?
| Feeding Behavior | 1 | 2016 | 185 | 0.030 |
Why?
| Aged, 80 and over | 1 | 2021 | 3226 | 0.030 |
Why?
| Inhibitory Concentration 50 | 2 | 2004 | 69 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 745 | 0.030 |
Why?
| Culture Media | 2 | 2004 | 93 | 0.030 |
Why?
| Glucocorticoids | 1 | 2015 | 230 | 0.030 |
Why?
| Bone Resorption | 1 | 2016 | 302 | 0.030 |
Why?
| Chronic Disease | 1 | 2015 | 573 | 0.030 |
Why?
| DNA Breaks, Double-Stranded | 1 | 2013 | 65 | 0.030 |
Why?
| Decision Making | 1 | 2015 | 272 | 0.030 |
Why?
| Light | 1 | 2013 | 69 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2016 | 1585 | 0.020 |
Why?
| Mutation | 1 | 2018 | 1280 | 0.020 |
Why?
| Computer-Aided Design | 1 | 2011 | 22 | 0.020 |
Why?
| Equipment Failure Analysis | 1 | 2011 | 45 | 0.020 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2011 | 3 | 0.020 |
Why?
| Phantoms, Imaging | 1 | 2011 | 122 | 0.020 |
Why?
| Equipment Design | 1 | 2011 | 289 | 0.020 |
Why?
| Volatilization | 1 | 2010 | 4 | 0.020 |
Why?
| Leukocyte Count | 1 | 2010 | 69 | 0.020 |
Why?
| Solvents | 1 | 2010 | 29 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2016 | 784 | 0.020 |
Why?
| Geography | 1 | 2010 | 60 | 0.020 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2009 | 31 | 0.020 |
Why?
| Air | 1 | 2009 | 22 | 0.020 |
Why?
| Amides | 1 | 2009 | 35 | 0.020 |
Why?
| Retrospective Studies | 1 | 2022 | 6263 | 0.020 |
Why?
| Dogs | 1 | 2009 | 186 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 68 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2009 | 20 | 0.020 |
Why?
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 27 | 0.020 |
Why?
| Thermal Conductivity | 1 | 2009 | 7 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| Binding, Competitive | 1 | 2009 | 94 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2010 | 326 | 0.020 |
Why?
| Pharmacokinetics | 1 | 2008 | 17 | 0.020 |
Why?
| Child | 1 | 2021 | 6906 | 0.020 |
Why?
| Models, Statistical | 1 | 2010 | 226 | 0.020 |
Why?
| Guinea Pigs | 1 | 2008 | 75 | 0.020 |
Why?
| Drug Design | 1 | 2009 | 119 | 0.020 |
Why?
| Isatin | 1 | 2008 | 1 | 0.020 |
Why?
| Auditory Threshold | 1 | 2008 | 49 | 0.020 |
Why?
| Bone Marrow | 1 | 2010 | 363 | 0.020 |
Why?
| Probability | 1 | 2008 | 164 | 0.020 |
Why?
| Weight Loss | 1 | 2010 | 245 | 0.020 |
Why?
| Glycosylphosphatidylinositols | 1 | 2007 | 32 | 0.020 |
Why?
| Crystallography, X-Ray | 1 | 2008 | 147 | 0.020 |
Why?
| Recurrence | 1 | 2009 | 659 | 0.020 |
Why?
| Rubidium | 1 | 2006 | 4 | 0.020 |
Why?
| Isoelectric Point | 1 | 2005 | 4 | 0.020 |
Why?
| Isoelectric Focusing | 1 | 2005 | 8 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2009 | 978 | 0.020 |
Why?
| Caffeine | 1 | 2006 | 64 | 0.020 |
Why?
| Peptide Mapping | 1 | 2005 | 21 | 0.020 |
Why?
| Air Movements | 1 | 2005 | 1 | 0.020 |
Why?
| Liver | 1 | 2011 | 1132 | 0.020 |
Why?
| Cell Cycle | 1 | 2006 | 226 | 0.010 |
Why?
| Quality Control | 1 | 2005 | 98 | 0.010 |
Why?
| Tumor Stem Cell Assay | 1 | 2004 | 17 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2007 | 367 | 0.010 |
Why?
| Tennessee | 1 | 2003 | 36 | 0.010 |
Why?
| HL-60 Cells | 1 | 2003 | 18 | 0.010 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2009 | 519 | 0.010 |
Why?
| Solubility | 1 | 2003 | 71 | 0.010 |
Why?
| Cyclin B | 1 | 2003 | 4 | 0.010 |
Why?
| Cyclin B1 | 1 | 2003 | 5 | 0.010 |
Why?
| Water | 1 | 2003 | 76 | 0.010 |
Why?
| CDC2 Protein Kinase | 1 | 2003 | 16 | 0.010 |
Why?
| Heat-Shock Proteins | 1 | 2003 | 100 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2004 | 1548 | 0.010 |
Why?
|
|
Griffin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|